Expanding the Huntington’s disease research toolbox; validated subdomain protein constructs for biochemical and structural investigation of huntingtin

Huntington’s disease is characterised by CAG expansion in the huntingtin gene above a critical threshold of ~35 repeats, resulting in polyglutamine expansion of the huntingtin protein (HTT). The biological role of wildtype HTT and the associated mechanisms of disease pathology caused by expanded HTT remain incompletely understood, in part, due to challenges characterising interactions between HTT and putative binding partners. Here we describe a biochemical toolkit of rationally designed, high-quality recombinant HTT subdomains; one spanning the N-terminal HEAT and bridge domains (NTD) and the second spanning the C-terminal HEAT domain (CTD). Using biophysical methods and cryo-electron microscopy, we show these smaller subdomains are natively folded and can associate to reconstitute a functional full-length HTT structure capable of forming a near native-like complex with 40 kDa HTT-associated protein (HAP40). We report biotin-tagged variants of these subdomains, as well as full-length HTT, that permit immobilisation of each protein for quantitative biophysical assays without impacting protein quality. We demonstrate the CTD alone can form a stable complex when co-expressed with HAP40, which can be structurally resolved. The CTD-HAP40 complex binds the NTD, with a dissociation constant of approximately 10 nM as measured by bio-layer interferometry. We validate the interaction between the CTD and HAP40 using a luciferase two-hybrid assay and use subdomain constructs to demonstrate their respective stabilization of HAP40 in cells. These open-source biochemical tools will enable the wider HD community to study fundamental HTT biology, discover new macromolecular or small-molecule binding partners and map interaction sites across this very large protein.

[1]  H. Taguchi,et al.  Conversion of a PROTAC Mutant Huntingtin Degrader into Small-Molecule Hydrophobic Tags Focusing on Drug-like Properties. , 2022, ACS medicinal chemistry letters.

[2]  E. Wanker,et al.  Dynamics of huntingtin protein interactions in the striatum identifies candidate modifiers of Huntington disease. , 2022, Cell systems.

[3]  A. Heck,et al.  Huntingtin structure is orchestrated by HAP40 and shows a polyglutamine expansion-specific interaction with exon 1 , 2021, Communications Biology.

[4]  K. Lindenberg,et al.  HAP40 protein levels are huntingtin-dependent and decrease in Huntington disease , 2021, Neurobiology of Disease.

[5]  W. Baumeister,et al.  PolyQ expansion does not alter the Huntingtin-HAP40 complex , 2021, bioRxiv.

[6]  Daphne Lelieveld,et al.  Discovery of small molecules that induce lysosomal cell death incancer cells using a phenotypic screening platform , 2021 .

[7]  Cyril F. Reboul,et al.  SIMPLE 3.0. Stream single-particle cryo-EM analysis in real time. , 2020, Journal of structural biology.

[8]  D. Marchionini,et al.  HAP40 is a conserved central regulator of Huntingtin and a specific modulator of mutant Huntingtin toxicity , 2020, bioRxiv.

[9]  Vicky L Brandt,et al.  Traffic signaling: new functions of huntingtin and axonal transport in neurological disease , 2020, Current Opinion in Neurobiology.

[10]  E. Wanker,et al.  The pathobiology of perturbed mutant huntingtin protein–protein interactions in Huntington's disease , 2019, Journal of neurochemistry.

[11]  Matthieu Schapira,et al.  Targeted protein degradation: expanding the toolbox , 2019, Nature Reviews Drug Discovery.

[12]  M. Li,et al.  Reduced mitochondrial fusion and Huntingtin levels contribute to impaired dendritic maturation and behavioral deficits in Fmr1 mutant mice , 2019, Nature Neuroscience.

[13]  C. Arrowsmith,et al.  Design and characterization of mutant and wildtype huntingtin proteins produced from a toolkit of scalable eukaryotic expression systems , 2019, The Journal of Biological Chemistry.

[14]  M. Rosenau Data availability , 2018 .

[15]  Sigrid Schnoegl,et al.  LuTHy: a double‐readout bioluminescence‐based two‐hybrid technology for quantitative mapping of protein–protein interactions in mammalian cells , 2018, Molecular systems biology.

[16]  N. Chen,et al.  Blockade of the swelling-induced chloride current attenuates the mouse neonatal hypoxic-ischemic brain injury in vivo , 2018, Acta Pharmacologica Sinica.

[17]  Y. Hashimoto,et al.  Discovery of Small Molecules that Induce the Degradation of Huntingtin. , 2017, Angewandte Chemie.

[18]  David J. Fleet,et al.  cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination , 2017, Nature Methods.

[19]  S. Humbert,et al.  The Biology of Huntingtin , 2016, Neuron.

[20]  H. Bellen,et al.  Huntingtin Functions as a Scaffold for Selective Macroautophagy , 2015, Nature Cell Biology.

[21]  R. Truant,et al.  A huntingtin-mediated fast stress response halting endosomal trafficking is defective in Huntington's disease. , 2015, Human molecular genetics.

[22]  M. Howarth,et al.  Site-specific biotinylation of purified proteins using BirA. , 2015, Methods in molecular biology.

[23]  David E. Housman,et al.  Extensive changes in DNA methylation are associated with expression of mutant huntingtin , 2013, Proceedings of the National Academy of Sciences.

[24]  M. Hayden,et al.  A fully humanized transgenic mouse model of Huntington disease. , 2013, Human molecular genetics.

[25]  R. Cole,et al.  Huntingtin protein interactions altered by polyglutamine expansion as determined by quantitative proteomic analysis , 2012, Cell cycle.

[26]  J. Yates,et al.  Proteomic Analysis of Wild-type and Mutant Huntingtin-associated Proteins in Mouse Brains Identifies Unique Interactions and Involvement in Protein Synthesis* , 2012, The Journal of Biological Chemistry.

[27]  R. Atwal,et al.  Kinase inhibitors modulate huntingtin cell localization and toxicity. , 2011, Nature chemical biology.

[28]  R. Roos,et al.  Huntington's disease: a clinical review , 2010, Orphanet journal of rare diseases.

[29]  John Mitchell,et al.  Small Molecule Immunosensing Using Surface Plasmon Resonance , 2010, Sensors.

[30]  M. MacDonald,et al.  Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models , 2009, Neurobiology of Disease.

[31]  F. Niesen,et al.  The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability , 2007, Nature Protocols.

[32]  Richard G. Brusch,et al.  Disruption of Axonal Transport by Loss of Huntingtin or Expression of Pathogenic PolyQ Proteins in Drosophila , 2003, Neuron.

[33]  R. Deshaies,et al.  Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[34]  P Bork,et al.  Comparison of ARM and HEAT protein repeats. , 2001, Journal of molecular biology.

[35]  C. Ross,et al.  Isolation of a 40-kDa Huntingtin-associated Protein* , 2001, The Journal of Biological Chemistry.